Crizotinib – a tyrosine kinase inhibitor that stimulates immunogenic cell death

Crizotinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of non-small cell lung cancers (NSLCL) and lymphomas expressing activating translocations or mutations of oncogenic tyrosine kinases (in particular ALK and ROS1). We recently observed that high-dose (final concentration in vi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncoimmunology
Main Authors: Liu, Peng, Zhao, Liwei, Kepp, Oliver, Kroemer, Guido
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2019
Fag:
Editorial
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6527279/
https://ncbi.nlm.nih.gov/pubmed/31143519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1596652
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker